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Colorectal cancer is the leading type of cancer in most
developed countries. In more than half of all patients
with colorectal cancer, surgery alone or surgery combined
with adjuvant therapy, is the main way of treating
the disease. Carcinoma of the rectum constitutes
approximately one-third of these and will alone affect
more than 3842 persons in Poland annually. A debate
concerning the surgical strategies for rectal carcinoma
treatment has been held over the years. Many surgeons
agree that the technical component of operative
treatment of rectal carcinoma is important for the
outcome. Local control and overall outcome after
treatment for rectal cancer are clearly related to the
adequacy of the surgical procedure. Local recurrence
rates of 3 to 43% are reported in various series for
surgical treatment of rectal cancer. Surgeons all over the
world have been trying to find the “golden” technical
procedure to achieve the main goals in successful
operative treatment: complete tumour resection,
prevention of local and systemic metastasis, nerve-sparing
and preservation of the postoperative bladder and
sphincter as well as sexual functions. As documented,
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Rectal cancer remains one of the most common malignancies in many countries. For decades the "golden standard" treatment
for rectal cancer was abdomino-perineal excision (APE) based on Miles' concept of rectal cancer spreading. This conventional
surgery (manual or blind dissection) has been associated with local recurrence rates of 20 to 45% and a five-year disease-free
survival rate of some 50%.
A new era for rectal surgery started in 1982 when Heald introduced the total mesorectum excision technique (TME). From this
time we have seen great changes in surgical results for rectal cancer.
Patients undergoing only surgical treatment in the form of TME, local recurrence rates were between 3% and 8% and five-year
disease-free survival rates were up to 85%. The main technical distinction between TME and conventional surgery is the use
of sharp instrument dissection under direct vision, following a defined plane between the visceral and the parietal layers of the
pelvic fascia.
The TME technique has now been well accepted worldwide due to its excellent results in lowering the rate of local recurrence
and successful overall survival after rectal surgery We postulate that the TME technique should be the standard procedure in
rectal cancer surgery in Poland.
Ca∏kowite wyci´cie mezorectum (TME) w leczeniu raka odbytnicy
Rak odbytnicy jest jednym z najcz´stszych nowotworów w wielu krajach. Z∏otym standardem w leczeniu tego nowotworu przez
dziesi´ciolecia by∏o brzuszno-kroczowe odj´cie odbytnicy, bazujàce na za∏o˝eniach Miles'a, dotyczàcych dróg szerzenia si´ tego
nowotworu. Ten tradycyjny sposób operowania (na t´po, bez kontroli wzroku) zwiàzany by∏ z 20 do 45% nawrotów
miejscowych i prze˝yciami pi´cioletnimi do 50%.
Nowy rozdzia∏ w chirurgii raka odbytnicy rozpoczà∏ si´ w 1982 r. kiedy Heald przedstawi∏ technik´ ca∏kowitego wyci´cia
mezorectum (TME). Od tego czasu obserwujemy znaczàce post´py w wynikach leczenia operacyjnego raka odbytnicy.
U pacjentów poddanych wy∏àcznie leczeniu chirurgicznemu sposobem TME stwierdzono nawroty miejscowe wg ró˝nych
autorów od 3% do 8%, a pi´cioletnie prze˝ycia do 85%.
Podstawowa ró˝nica pomi´dzy technikà TME a konwencjonalnym sposobem polega na operowaniu na ostro, pod kontrolà
wzroku, pomi´dzy ÊciÊle zdefiniowanymi powierzchniami powi´zi trzewnej i Êciennej miednicy ma∏ej. Technika TME znalaz∏a
obecnie szerokie uznanie w Êwiecie, w zwiàzku z doskona∏ymi wynikami, polegajàcymi na obni˝eniu odsetka nawrotów
miejscowych i poprawie ca∏kowitego prze˝ycia po leczeniu chirurgicznym. W zwiàzku z tym postulujemy, by technika
ca∏kowitego wyci´cia mezorectum sta∏a si´ standardem w leczeniu chirurgicznym raka odbytnicy w Polsce.
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these aims are not attainable using the older, conventional
type of surgery, called blunt or manual dissection.
Abdominoperineal excision (APE) is commonly used
during blunt dissection. For many decades APE was the
dominant surgical procedure and the “golden standard”
treatment for rectal adenocarcinoma, particularly of the
lower one-third of the rectum. APE has been performed
on many millions of patients, and it has probably cured
less than one-fourth of them. Heald and co-workers like
to call APE an “endangered operation” [1]. This
conventional surgery is based on the Miles concept of
rectal cancer spread [2]. He considered the levators, the
ischiorectal fat, sphincters and the perianal skin, as tissues
with tumor spread and suggested their resection. During
the procedure the surgeon, without direct vision, inserts
the hand into the loose areolar tissue by the rectosacral
ligament – the fusion of the parietal and visceral layers of
the pelvic fasciae – towards the mesorectum, the fatty
layer surrounding the rectal bowel wall where visceral
branches and regional lymph nodes are situated. The
main focus is based on macroscopic tumor removal and
the distal resection margin. However, less attention is
paid to the preservation of mesorectal integrity and to
careful dissection of lateral ligaments containing
autonomic nerves. In general, as a consequence of the
latter (nerve injury), postoperative sexual and bladder
dysfunction is often reported by patients [3-5]. Moreover,
inadequate resection of the mesorectum performed
without definable tissue planes during blunt surgery
causes a higher risk of further metastasis, first, because
tumor cells extruding through the imperfectly occluded
anus may inoculate [1], and, second, because the
fragmented mesorectum left in the pelvis with its lymph
nodes (often positive for metastatic spread) may serve
as a source for further local recurrences approximately 18
months later [6]. Local failure rates after blunt dissection
are as high as 20-45% [7-9].
A new era for rectal surgery started in 1982, when
Heald first introduced the technique Total Mesorectal
Excision (TME) [10], also called Circumferential
Mesorectal Excision [6], Sharp Mesorectal Excision,
Extrafascial Excision of the Rectum and Total Anatomical
Dissection. Heald postulated that inadequate mesorectal
excision is the cause of local recurrences and that all
cancers of the middle and lower third rectum should be
excised with the mesorectum left intact. Heald had
demonstrated that not the pelvic fascia, which is an
“almost impenetrable barrier to the spread of carcinoma”
[11, 12], but the mesorectum is the main tissue for
neoplastic spread in rectal cancer via lymphatic flow
[10, 13, 14]. The visceral fascia envelopes the rectum
and the mesorectum. The parietal fascia covers the
musculoskeletal and vascular boundaries of the sidewalls,
including the pelvic autonomic nerves and plexuses.
Heald's concept was further supported by histopatho-
logical evaluations by Quirke's group. Quirke and other
authors showed that the left circumferential margin
carries a risk of local failure greater than 80% [15-17].
Lateral resection margin involvement with surgical
clearance of ≤1mm in a single slice, assessed by histo-
pathology, is considered unsatisfactory and is associated
with a poor prognosis and the failure of surgery [18, 17].
As indicated, 29% of patients with a positive margin and
only 8% of patients with a negative margin developed
local recurrences [19]. The main attention paid by
surgeons preceding TME is the removal of the whole
visceral mesentery of the rectum without leaving
a substantial circumferential and distal residue. The basic
principles and the main differences between conventional
surgery (APE) and TME are illustrated in Figure 1. The
correct plane is definable and avascular, and sharp
dissection without tearing the surface is performed with
direct vision down into the pelvis around the area of the
rectum with the tumor and along the surface of the fatty,
lymphovascular mesorectum five cm below the tumor.
Muscle margin may be reduced to one up to two cm [7,
14, 20, 21]. During the procedure every effort is made to
preserve mesorectal integrity together with an awareness
of the lateral rectal ligaments containing the pelvic
autonomic nerve plexus, since damage to the latter may
have drastic consequences on postoperative bladder
and sexual functions. Besides the pelvic autonomic
nerves, the following nerves should also be untouched:
the superior hypogastric nerve and anterior nerve
roots S2, S3 and S4. Lower local recurrences and a higher
survival rate, better levator muscle and sphincter (anus)
preservation together with pelvic autonomic and plexus
preservation, as well as avoidance of sexual and urinary
morbidity, are all main goals of modern rectal surgery
achievable by TME, especially with use of low stapled
anastomosis (the latter being used to maximize sphincter
preservation) [5, 8, 22]. Local recurrence as low as 3-8%
at five years and long-term survivals of over 80% after
complete excision achieved without any additional
adjuvant therapy were reported by several authors [7-9,
23-28] (Table I). These dramatic improvements are all
attributable to the more complete resection accomplished
by fundamental changes in the surgical technique. The
technical distinction between TME and conventional
surgery is the use of sharp instrument dissection under
direct vision, following a defined plane between the
visceral and the parietal layers of the pelvic fascia [8]. It
should be stressed that the precision, skill and experience
of the surgeon performing the procedure are no less
Figure 1. Postoperative specimen – crossection
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important than the chosen technique. Hermanek and co-
workers have reported a variation from 4% to 55% of
local recurrences among 43 surgeons (594 patients) [29].
Notably, the technique routinely used by Japanese
colleagues with extended pelvic lymphadenectomy in
which both mesenteric and extramesenteric lymphatic
tissues are removed is still unproven in Western countries
[30]. A radical resection of the retroperitoneum between
the ureters and laying bare the inferior rena core and
aorta and sacral nerve roots in the pelvis are performed.
As documented, this extremely radical procedure is highly
dangerous for the preservation of urinary and sexual
functions since the autonomic nerves are damaged: 30%
of patients had urinary problems and more than 70%
experienced sexual dysfunction [31].
The other unsolved and very controversial surgical
dilemma in rectal cancer continues to be the application
of neoadjuvant therapy along with operation procedures.
More retrospective or/and more new studies should be
undertaken to evaluate and establish such a need.
Especially now when the new surgical technique of TME
has highly improved and dramatically lowered local
failure even without the addition of adjuvant therapy,
should recommendations for radiochemotherapy be
reconsidered [32] (Table II). Zaheer concludes that
although each successful surgery gives a low rate of local
recurrences and good long-term survival, in some
instances such as stage III disease, surgical treatment
alone is probably not sufficient [26]. Presently there is
a discussion about current standard treatments based
primarily on applications of radiotherapy to all patients
with stage II and III diseases as well as about preoperative
intensive short-course radiation for all patients [33, 34].
One concept for future exploration concerns a multi-
modal treatment based on pathological/molecular
features of an individual patient, sophisticated imaging
approaches combined innovative surgical sphincter-
preserving techniques (includingTME), and improved
radiation techniques as well as innovative schedules
and combinations of chemotherapy. However, Heald
postulates that instead of investments in money-
consuming multimodal treatments, it would be more
clever to invest in the improvement of surgical skills as
these latter are the most beneficial both for patients and
long-term costs of rectal cancer treatment [35, 36]. The
skill of the surgeon is an important independent variable
in preventing local recurrence and increasing survival.
The rectum must be dissected anatomically under direct
vision and not removed by manual extraction, which was
common in the past [10, 14, 24].
The TME technique has now been accepted
worldwide due to its excellent results in lowering the rate
of local recurrence and successful overall survival after
rectal surgery alone. In countries such as Norway,
Sweden, Denmark and Holland, TME is the national
standard; in Germany, France and the UK the TME
concept is supported. The TME technique involves sharp
excision with direct vision down into the pelvis around
the area of the rectum with tumor and extirpation of the
mesorectum by dissecting outside the mesorectum on the
endopelvic fascia. In conclusion, we postulate that the
TME technique should as well be the standard procedure
in rectal cancer surgery in Poland.
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